iCAD (NASDAQ:ICAD) Stock Rating Upgraded by StockNews.com

iCAD (NASDAQ:ICAD) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

iCAD Trading Down 2.7 %

Shares of NASDAQ ICAD opened at $2.14 on Wednesday. The company has a market capitalization of $56.80 million, a P/E ratio of -16.46 and a beta of 1.95. iCAD has a 12 month low of $1.18 and a 12 month high of $3.78. The stock has a 50 day moving average of $2.68 and a 200-day moving average of $2.08.

iCAD (NASDAQ:ICAD) last posted its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The company had revenue of $5.41 million during the quarter, compared to analysts’ expectations of $4.72 million. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. waypoint wealth counsel boosted its holdings in iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after purchasing an additional 4,400 shares during the period. Thompson Davis & CO. Inc. bought a new position in iCAD in the fourth quarter valued at approximately $31,000. PKS Advisory Services LLC acquired a new position in shares of iCAD during the 4th quarter worth $53,000. Wells Fargo & Company MN lifted its holdings in shares of iCAD by 51.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock worth $72,000 after acquiring an additional 13,402 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of iCAD in the 4th quarter valued at approximately $92,000. Institutional investors own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.